Health

Wipro and Intel backed customer experience platform developer Lilt's $55m series C while Pfizer is buying corporate-backed respiratory virus therapeutic developer ReViral for up to $525m.

China Life Private Equity Investment and PICC Capital returned to co-lead the pharmaceutical discovery technology provider’s latest rounds, four months after it emerged from stealth.

The Global University Venturing deal net rounds up the smaller investments from across the university innovation ecosystem.

Mitsui took part in oncology therapy developer Ensem Therapeutics' $67m series A round while Bioventus is paying up to $450m to buy the rest of portfolio company CartiHeal.

The drug retailer’s AB Health Ventures unit will focus on early to mid-stage healthcare technology providers working on areas including pharmaceutical distribution, commercialisation and pet care.

The gut microbiome drug developer went public in a $22.5m offering priced at the foot of its range.

SoftBank Vision Fund 2 led the healthcare management software provider’s series D round, taking its overall funding to about $213m and its valuation to a reported $1.4bn.

The company, which largely remains in stealth mode, has set itself a mission of increasing the human lifespan by a decade.

The Global University Venturing deal net rounds up the smaller investments from across the university innovation ecosystem.

Kaiser Permanente Ventures returned to reinvest in the nursing staff management service at a $1.1bn valuation.

The Macrogen-backed gut microbiome drug developer went public in a $22.5m offering priced at the foot of its range.